The cerebral and vascular plaques associated with Alzheimer′s disease (AD) are mainly composed of amyloid beta peptides (Aβ). Aβ is derived from cleavage of the amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. Aβ [1-40], Aβ [1-42], and Aβ [1-43] peptides result from cleavage of APP after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last APP processing step. Aβ [1-40], [1-42] and [1-43] peptides are major constituents of the plaques and tangles that occur in AD. Aβ antibodies and peptides have been developed as tools for elucidating the biology of AD.
This antibody recognizes Amyloid β40 at the C-terminus.
Linear peptide of human Amyloid β40 at the C terminus.
Immunohistochemistry Analysis: 1:300 dilution from a previous lot detected Amyloid β40 in Alzheimer’s diseased hippocampus tissue.
Detect Amyloid β40 using this Anti-Amyloid β40 Antibody, clone G2-10 validated for use in WB, IH, ELISA.
Research Sub Category
Evaluated by Western Blot in APP transgenic CRND8 mouse brain lysate.
Western Blot Analysis: 1 µg/ml of this antibody detected Amyloid β40 on 10 µg of APP transgenic CRND8 mouse brain lysate.
~ 4 kDa
Protein G Purified
Purified mouse monoclonal IgG2bκ in buffer containing 0.1 M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.05% sodium azide and 1% BSA.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
APP transgenic CRND8 mouse brain lysate
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.